在 COVID-19 大流行期间照顾糖尿病患者：药师的重要考虑因素。
Caring for patients with diabetes during COVID-19 pandemic: Important considerations for pharmacists.
机构信息
Department of Pharmacy Practice, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia; Quality Use of Medicines Research Group, Faculty of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia.
School of Pharmacy, University of Birmingham, Edgbaston, Birmingham, UK.
出版信息
Res Social Adm Pharm. 2021 Jan;17(1):1938-1941. doi: 10.1016/j.sapharm.2020.05.030. Epub 2020 May 31.
Abstract
The current pandemic of the COVID-19 infection, coupled with the increased global burden of diabetes, has imposed significant challenges to the healthcare providers in providing effective and sustained care to patients with diabetes during the ongoing pandemic. It is, therefore, important for healthcare providers to understand and follow the recommended changes in the delivery of care, lifestyle modifications, and pharmacotherapy to ensure optimal care to the patients during and post-pandemic era. This commentary aims to discuss the impact of COVID-19 on diabetes care and the important considerations for pharmacists during this pandemic.
摘要
当前 COVID-19 感染的大流行，加上糖尿病全球负担的增加，给医疗保健提供者在大流行期间为糖尿病患者提供有效和持续的护理带来了重大挑战。因此，医疗保健提供者了解并遵循护理、生活方式改变和药物治疗方面的推荐变化非常重要，以确保在大流行期间和之后为患者提供最佳护理。本评论旨在讨论 COVID-19 对糖尿病护理的影响，以及在这场大流行期间药师的重要考虑因素。
相似文献
1
Caring for patients with diabetes during COVID-19 pandemic: Important considerations for pharmacists.在 COVID-19 大流行期间照顾糖尿病患者：药师的重要考虑因素。
Res Social Adm Pharm. 2021 Jan;17(1):1938-1941. doi: 10.1016/j.sapharm.2020.05.030. Epub 2020 May 31.
2
FIP's response to the COVID-19 pandemic: Global pharmacy rises to the challenge.FIP 应对 COVID-19 大流行的举措：全球药剂师迎难而上。
Res Social Adm Pharm. 2021 Jan;17(1):1929-1933. doi: 10.1016/j.sapharm.2020.07.004. Epub 2020 Jul 10.
3
Community pharmacists and communication in the time of COVID-19: Applying the health belief model.社区药剂师与 COVID-19 时期的沟通：应用健康信念模型。
Res Social Adm Pharm. 2021 Jan;17(1):1984-1987. doi: 10.1016/j.sapharm.2020.03.017. Epub 2020 Mar 26.
4
COVID-19 related regulatory change for pharmacists - The case for its retention post the pandemic.与 COVID-19 相关的药剂师监管法规变化——大流行后保留该法规的理由。
Res Social Adm Pharm. 2021 Jan;17(1):1913-1919. doi: 10.1016/j.sapharm.2020.07.037. Epub 2020 Aug 22.
5
Global drug shortages due to COVID-19: Impact on patient care and mitigation strategies.全球因 COVID-19 导致的药品短缺：对患者护理的影响和缓解策略。
Res Social Adm Pharm. 2021 Jan;17(1):1946-1949. doi: 10.1016/j.sapharm.2020.05.017. Epub 2020 May 19.
6
Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective.在 COVID-19 大流行期间提供药学服务的建议和指导：中国视角。
Res Social Adm Pharm. 2021 Jan;17(1):1819-1824. doi: 10.1016/j.sapharm.2020.03.012. Epub 2020 Mar 26.
7
The legal extension of the role of pharmacists in light of the COVID-19 global pandemic.在 COVID-19 全球大流行背景下，药师作用的法律延伸。
Res Social Adm Pharm. 2021 Jan;17(1):1807-1812. doi: 10.1016/j.sapharm.2020.05.033. Epub 2020 Jun 12.
8
Creation of a Diabetes Pharmacists Network in Canada.在加拿大创建糖尿病药剂师网络。
Can J Diabetes. 2017 Dec;41(6):571-575. doi: 10.1016/j.jcjd.2017.08.001.
9
COVID-19 pandemic: The role of community pharmacists in chronic kidney disease management supportive care.COVID-19 大流行：社区药剂师在慢性肾脏病管理支持性护理中的作用。
Res Social Adm Pharm. 2021 Jan;17(1):1925-1928. doi: 10.1016/j.sapharm.2020.07.008. Epub 2020 Jul 8.
10
On the frontline against COVID-19: Community pharmacists' contribution during a public health crisis.在抗击 COVID-19 的前线：公共卫生危机期间社区药剂师的贡献。
Res Social Adm Pharm. 2021 Jan;17(1):2032-2035. doi: 10.1016/j.sapharm.2020.03.015. Epub 2020 Mar 31.
引用本文的文献
1
Functions of mHealth Diabetes Apps That Enable the Provision of Pharmaceutical Care: Criteria Development and Evaluation of Popular Apps.移动医疗糖尿病应用程序实现药学服务的功能：标准制定与大众应用程序评估。
Int J Environ Res Public Health. 2022 Dec 21;20(1):64. doi: 10.3390/ijerph20010064.
2
Factors associated with disease severity of COVID‑19 in patients with type 2 diabetes mellitus.2型糖尿病患者中与新冠病毒病严重程度相关的因素。
Biomed Rep. 2022 Nov 29;18(1):8. doi: 10.3892/br.2022.1590. eCollection 2023 Jan.
3
Diabetes care and prevention services provided by pharmacists: Progress made during the COVID-19 pandemic and the need for additional efforts in the post-pandemic era.药剂师提供的糖尿病护理与预防服务：COVID-19大流行期间取得的进展以及大流行后时代进一步努力的必要性。
Explor Res Clin Soc Pharm. 2022 Jun;6:100137. doi: 10.1016/j.rcsop.2022.100137. Epub 2022 Apr 20.
4
COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter?马来西亚民众对新冠疫苗接种的态度、认知及副作用体验：年龄、性别和疫苗类型有影响吗？
Vaccines (Basel). 2021 Oct 9;9(10):1156. doi: 10.3390/vaccines9101156.
5
Associations between Socio-Demographic Factors and Hypertension Management during the COVID-19 Pandemic: Preliminary Findings from Malaysia.社会人口因素与 COVID-19 大流行期间高血压管理的关系：来自马来西亚的初步发现。
Int J Environ Res Public Health. 2021 Sep 3;18(17):9306. doi: 10.3390/ijerph18179306.
6
Ketonuria with or without ketoacidosis as the presenting manifestation of SARS-CoV-2 (COVID-19) among uncontrolled type 2 diabetic patients.在未控制的 2 型糖尿病患者中，以酮尿伴或不伴酮症酸中毒为表现的 SARS-CoV-2（COVID-19）。
Med Hypotheses. 2020 Nov;144:110226. doi: 10.1016/j.mehy.2020.110226. Epub 2020 Sep 2.
本文引用的文献
1
Glycemic Control and Infections Among US Hemodialysis Patients With Diabetes Mellitus.美国糖尿病血液透析患者的血糖控制与感染情况
Kidney Int Rep. 2020 Apr 29;5(7):1014-1025. doi: 10.1016/j.ekir.2020.04.020. eCollection 2020 Jul.
2
COVID-19 pandemic: Response plan by the Johns Hopkins Aramco Healthcare inpatient pharmacy department.COVID-19 大流行：约翰霍普金斯阿美石油公司医疗保健住院药房部门的应对计划。
Res Social Adm Pharm. 2021 Jan;17(1):2009-2011. doi: 10.1016/j.sapharm.2020.05.016. Epub 2020 May 18.
3
Emerging from the other end: Key measures for a successful COVID-19 lockdown exit strategy and the potential contribution of pharmacists.走出疫情：成功的新冠疫情封锁退出策略的关键措施和药剂师的潜在贡献。
Res Social Adm Pharm. 2021 Jan;17(1):1950-1953. doi: 10.1016/j.sapharm.2020.05.011. Epub 2020 May 13.
4
COVID-19 and diabetes management: What should be considered?2019冠状病毒病与糖尿病管理：应考虑哪些方面？
Diabetes Res Clin Pract. 2020 May;163:108151. doi: 10.1016/j.diabres.2020.108151. Epub 2020 Apr 17.
5
Should anti-diabetic medications be reconsidered amid COVID-19 pandemic?在新冠疫情期间是否应重新考虑抗糖尿病药物？
Diabetes Res Clin Pract. 2020 May;163:108146. doi: 10.1016/j.diabres.2020.108146. Epub 2020 Apr 10.
6
Letter to the Editor: COVID-19 in patients with diabetes: Risk factors that increase morbidity.致编辑的信：糖尿病患者中的 COVID-19：增加发病率的风险因素。
Metabolism. 2020 Jul;108:154224. doi: 10.1016/j.metabol.2020.154224. Epub 2020 Apr 7.
7
COVID-19: immunopathology and its implications for therapy.新型冠状病毒肺炎：免疫病理学及其治疗意义。
Nat Rev Immunol. 2020 May;20(5):269-270. doi: 10.1038/s41577-020-0308-3.
8
Considerations for Statin Therapy in Patients with COVID-19.新型冠状病毒肺炎患者他汀类药物治疗的考量因素
Pharmacotherapy. 2020 May;40(5):484-486. doi: 10.1002/phar.2397. Epub 2020 May 4.
9
Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective.在 COVID-19 大流行期间提供药学服务的建议和指导：中国视角。
Res Social Adm Pharm. 2021 Jan;17(1):1819-1824. doi: 10.1016/j.sapharm.2020.03.012. Epub 2020 Mar 26.
10
COVID-19 pandemic, coronaviruses, and diabetes mellitus.COVID-19 大流行、冠状病毒和糖尿病。
Am J Physiol Endocrinol Metab. 2020 May 1;318(5):E736-E741. doi: 10.1152/ajpendo.00124.2020. Epub 2020 Mar 31.
Zotero 插件